+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Breast Cancer, An Issue of Hematology/Oncology Clinics of North America. The Clinics: Internal Medicine Volume 37-1

  • Book

  • November 2022
  • Region: North America
  • Elsevier Health Science
  • ID: 5658596
In this issue of Hematology/Oncology Clinics, guest editor Dr. Harold J. Burstein brings his considerable expertise to Breast Cancer. Top experts provide a comprehensive update on multidisciplinary management of early- and late-stage breast cancer, including key topics such as global perspectives on the epidemiology and treatment of breast cancer; breast cancer pathology in the era of genomics; optimizing radiation therapy after breast conserving surgery; and more.
  • Contains 16 relevant, practice-oriented topics including disparities in breast cancer outcomes and how to resolve them; genetic testing in breast cancer; the role of ovarian suppression in early stage premenopausal breast cancer; multidisciplinary management of brain metastases from breast cancer; evidence-based guidance for breast cancer survivorship; and more.�

  • Provides in-depth clinical reviews on breast cancer, offering actionable insights for clinical practice.�

  • Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.�

Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.

Table of Contents

Disparities in Breast Cancer Outcomes and How to Resolve Them

Testing for Inherited Susceptibility to Breast Cancer

Breast Cancer Pathology in the Era of Genomics

Breast Cancer Pathology in the Era of Genomics

Role of Ovarian Suppression in Early Premenopausal Breast Cancer

Adjuvant Systemic Therapy for Postmenopausal, Hormone Receptor-Positive Early Breast Cancer

Systemic Therapy for Early- and Late-Stage, Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer

Biology and Treatment of HER2-Low Breast Cancer

Role of Immunotherapy in Early- and Late-Stage Triple-Negative Breast Cancer

Current and Emerging Role of Antibody-Drug Conjugates in HER2-Negative Breast Cancer

The Clinical Utility of ESR1 Mutations in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

Multidisciplinary Management of Brain Metastasis from Breast Cancer

Systemic Therapy for Hereditary Breast Cancers

Evidence-Based Guidance for Breast Cancer Survivorship

Authors

Harold J. Burstein Professor of Medicine, Harvard Medical School, Staff Physician, Brigham And Women's Hospital.